Switch to Takhzyro found to reduce cardiovascular risk for HAE patient
Switching from long-term androgen treatment to Takhzyro (lanadelumab) successfully prevented swelling attacks and reduced cardiovascular risk in a man with hereditary angioedema (HAE) type 1, according to a report from Italy. The man had undergone two kidney transplants and was on immunosuppressant medications for several years. According to…